

Application Note

Compliant Monitoring of Monoclonal Antibody Titer and Primary Structure Attributes Using a 2D-LC-MS System with UNIFI Informatics

Brooke M. Koshel, Robert E. Birdsall, Ying Qing Yu

Waters Corporation

Abstract

In this work, 2D-LC/MS was used to assess monoclonal antibody (mAb) titer and confirm both product mass and glycosylation profile. The simplicity of data collection on a single platform configured for 1D titer measurements and 2D product profiling with MS detection is demonstrated.

Benefits

- Improved capabilities for mass detection through 2D coupling of incompatible methods.
 - Demonstrated flexibility for analysis of 1D and 2D analytical methods on a single platform with optical and/or MS detection.
 - Automated data acquisition and processing through utilization of compliant-ready UNIFI Software.
-

Introduction

Two-dimensional liquid chromatography (2D-LC) is used in many applications throughout the biopharmaceutical industry. As therapeutics become more complex and new modalities are being explored, there is a greater performance demand placed on analytical methods and instrumentation to provide high quality data for informed decision-making. Industry initiatives have also driven additional requirements for improved method robustness and operation under regulatory compliance. To address these evolving demands, 2D-LC with high-resolution mass spectrometry operating within compliant-ready UNIFI informatics is demonstrated. Protein A affinity chromatography coupled to reversed-phase mass spectrometry (Pro A-RPLC-MS) using a single heart-cut was used to assess titer and primary structure attributes. Experimental design was intended to be straightforward and was developed from several literature reports that have successfully coupled Pro A to various second dimension analyses.¹⁻³

Protein A affinity chromatography with optical detection is traditionally used for quantitation of Fc-containing molecules through purification from cell culture material. On an analytical scale, the assay is important for clone selection, where the highest producing cell lines are the most desirable. Once high titer is confirmed, additional assays that evaluate product quality attributes are also employed. In a general approach, samples of therapeutic molecules are purified from cell culture using preparative-scale chromatography or plate-based capture techniques, and one-dimensional (1D) assays such as size-exclusion chromatography (SEC), ion-exchange chromatography (IEX), and reversed-phase intact mass analysis would be run using the purified material. By using two-dimensional (2D) approaches, the need for excessive sample handling and downstream processing is eliminated.

In this work, 2D-LC-MS was used to assess monoclonal antibody (mAb) titer and confirm both product mass and glycosylation profile. The simplicity of data collection on a single platform configured for 1D titer measurements and 2D product profiling with MS detection is demonstrated.

Experimental

Sample description

Formulated trastuzumab at 21 mg/mL was used to prepare a stock concentration of 4 mg/mL trastuzumab in 0.1% formic acid (v/v) in water. A two-fold dilution series was prepared until the optical limit of detection was reached in the 1D Pro A study.

LC conditions

System:	ACQUITY UPLC I-Class PLUS with 2D Technology Quaternary solvent manager (QSM) (1st dimension) Binary solvent manager (BSM) (2nd dimension)
Detectors:	ACQUITY UPLC Tunable Ultraviolet (TUV) Detector (1st dimension)
Wavelength:	280 nm
Sample temp.:	6 °C
Injection vol.:	2 µL

Protein A (1st dimension)

Column:	POROS A 20 µm column, 2.1 × 30 mm
Column temp.:	25 °C
Flow rate:	1.000 mL/min
Mobile phase A:	50 mM phosphate, 150 mM NaCl, pH 7
Mobile phase B:	500 mM acetic acid

Gradient:

Time (min)	Flow rate (mL/min)	MPA (%)	MPB (%)	Curve
0.00	1.000	100.0	0.0	
1.50	1.000	100.0	0.0	6
1.51	1.000	0.0	100.0	6
4.50	1.000	0.0	100.0	6
4.51	1.000	100.0	0.0	6
9.00	1.000	100.0	0.0	6

Reversed-phase (2nd dimension)

Column: XBridge Protein BEH C₄, 300 Å, 3.5 µm, 4.6 × 50 mm (p/n: 186004502)

Column temp.: 80 °C

Flow rate: 0.500 mL/min (0.100 mL/min idle flow)

Mobile phase A: Water, 0.1% formic acid (v/v)

Mobile phase B: Acetonitrile, 0.1% formic acid (v/v)

Gradient:

Time (min)	Flow rate (mL/min)	MPA (%)	MPB (%)	Curve
0.00	0.500	95.0	5.0	
1.00	0.500	95.0	5.0	6
3.50	0.500	50.0	50.0	6
5.00	0.500	50.0	50.0	6
5.50	0.500	5.0	95.0	6
7.50	0.500	5.0	95.0	6
7.60	0.500	95.0	5.0	6
10.00	0.500	95.0	5.0	6

MS conditions

System:	Vion IMS QTof
Ionization mode:	ESI+, sensitivity mode
Mass range:	<i>m/z</i> 750–4000
Capillary voltage:	2.75 kV
Cone voltage:	140 V
Source temp.:	150 °C

Desolvation temp.:	600 °C
Desolvation gas flow:	600 L/Hr
Lockmass:	Glu fibrinopeptide B at 2.2 pmol/μL in 50/50 water/acetonitrile, 0.1% formic acid (v/v)

Data management

UNIFI Scientific Information System v1.9.4

Vion IMS QToF driver pack 2.2.0

Results and Discussion

1D Quantitation of Monoclonal Antibodies

Pro A with optical detection is often used as a stand-alone, high-throughput analytical assay for assessing mAb titer. In a traditional 1D titer assay, a calibration curve is produced using purified standards, and fit to a linear regression for quantification. The calibration curve shown in Figure 1 was generated from a trastuzumab dilution series (0.05, 0.1, 0.25, 0.5, 1.0, 2.0, and 4.0 mg/mL). An overlay of the injections from the dilution series shows repeatable retention time. The plot of peak area (TUV at 280 nm) versus concentration (mg/mL) of these injections shows high correlation, which is typical of this assay (inset).




Figure 1. Protein A affinity chromatography of trastuzumab standards. Overlay shows serial dilution with indicated mass load. Samples were prepared from 0.05–4 mg/mL, which corresponds to a mass load of 0.1–8 µg (2 µL injection volume). Calibration curve (inset) shows peak area versus concentration to be linear over this range.

RPLC-MS of intact mAbs can aid in clone selection, process development, and process monitoring by providing mass confirmation and a rapid profile of product glycosylation of the biotherapeutic. Although the Pro A buffer components are not directly compatible with mass analysis, 2D technology can be employed to selectively heart-cut the analyte of interest from the first dimension to the second-dimension column to run a second-dimension separation with MS-friendly eluents.

Configuring a 2D system within UNIFI is straightforward, and once the system is created, the user can readily

switch between using the system for a traditional 1D assay or the 2D workflow. Device Management can be accessed through the Administration tab to configure a 2D system (Figure 2). First dimension components should be added to the new system followed by second dimension components, which will then be assigned in that order within UNIFI for easy identification. This is especially useful when methods become more complex and additional pumps are incorporated, or a second column manager housing trap columns is required for a multiple heart-cut analysis.




Figure 2. 2D system configuration. To configure a chromatographic system, instrument components can easily be added or removed from a list of those available. First and second dimension modules can be added “in order” to distinguish one from the other. Independent systems can be created for 1D and 2D workflows respectively, and selected by the user prior to data collection.

The system configuration described in Figure 3 enables the user to switch between a traditional 1D workflow (Figure 3A) or modify the existing system to accommodate a 2D workflow through programming a series of valve switches, which can be carried out without any changes to system tubing connections. In this way, the 1D titler assay can serve as the workhorse for high-throughput screening when mass information isn’t necessary. When identity confirmation is required, a second injection of analyte can be made, and a heart-cut can be transferred to the second dimension (Figure 3B). When the heart-cut window is determined, the first- and second-dimension flow paths are combined through at-column dilution (ACD). By switching the valve positions back to the original position, the flow paths are once again isolated, and the second-dimension separation can be run (Figure 3C).




Figure 3. System configuration for 1D and 2D workflows. Flow is directed to an optical detector in a traditional 1D assay (3A). This same configuration is also used to monitor retention time repeatability in a 2D workflow. When it is determined when the analyte of interest elutes off the first dimension column, flow is re-directed to the second dimension (3B). ACD works to wash the sample with MS compatible mobile phase. The flow paths are then isolated once again, and the secondary pump is used to drive the second dimension separation (3C). For second

dimension analysis, an additional TUV detector can be placed in-line, which can aid in troubleshooting when developing methods. The eluent from column two can also be plumbed to bypass the optical detector to flow directly to MS.

Once the 2D system is configured in UNIFI, individual 1D and 2D methods can be created. From the Analysis Method, the field “Acquisition Method Name” is added to the Sample list setup so that the appropriate method can be selected for data acquisition (Figure 4A). Additional methods can also be created for de-salting or for independent runs in a multiple heart-cut analysis, but these additional steps are not required in the Pro A-RPLC-MS analysis. Once individual methods are created, a Sample Set can be created (Figure 4B) to automate execution of all methods within an analysis.

4A. Analysis Method → Sample List

4B. Sample Set → Acquire


Item name	Sample type	Acquisition Method Name	Sample position	Run time (min)	Injection volume (μL)	Replicates	Level	Processing options	Cone Voltage (V)	Capillary (kV)	Desolvation gas flow
Sample_1D	Unknown	ProA in 1D with 2D config	1:0.1	9.00	2.00	1			140	2.75	600
Sample_1D	Unknown	2D Dim1 HC	1:0.1	9.00	2.00	1			140	2.75	600
Sample_2D	Unknown	2D Dim2 HC	1:6.1	20.00	0.00	1			140	2.75	600

Figure 4. Creating methods for 2D data collection. The field “Acquisition Method Name” must be incorporated into the analysis method so that independent 1D and 2D methods can be created. Once this field is selected as a promoted parameter, the user can queue-up individual acquisition methods. Methods shown are for 1D Pro A, 1D Pro A heart-cut, and 2D RPLC-MS.

Pro A-RPLC/MS Workflow


Using the methods detailed in Figure 4, the Pro A 1D method was used to determine mAb titer (Figure 5A). Peak area from the optical trace was used to calculate sample concentration from the calibration curve shown in Figure 1. In this example, the sample was determined to have a concentration of approximately 1 mg/mL. This same optical trace also determines the heart-cut window for transferring analyte to the second dimension for LC-MS analysis. In a second injection, a heart-cut window of 0.1 min (1.9–2.0 min) was selected to transfer analyte to the in-line second-dimension column. In the third line of the sample set, the flow paths are once again isolated, and a 10-minute isocratic hold is incorporated to wash the transferred analyte, which is adsorbed to the head of the second-dimension column, to remove protein A buffer contaminants. After the wash step, a 10-minute RPLC-MS gradient method was run. Figure 5B shows the resulting deconvoluted data for trastuzumab with labelled glycoforms. This mass data can be used to confirm sample identity through comparison to the predicted mass calculated from a reference standard. Monitoring glycosylation patterns can be routinely employed to screen for optimal biosimilar candidates, guide process development decisions, or potentially supply data for at-line analyses in manufacturing operations.

5A. 1D TUV



5B. ²D Deconvolution

Trastuzumab



NIST mAb




Figure 5. Pro A-RPLC-MS workflow. Protein A can be used to determine mAb titer by relating peak area to the

calibration curve shown in Figure 1. A 0.1 minute heart-cut window was then used to transfer analyte to the second dimension to collect MS data. The resulting deconvoluted spectrum is shown with identified glycoforms. Changes in mass as well as relative abundance can be observed when comparing trastuzumab to NIST mAb.

Conclusion

This work demonstrates how a traditional 1D assay can be extended to incorporate 2D functionality using a common instrument platform. The UNIFI Scientific Information System enables automated switching between 1D and 2D workflows, as needed, without making physical changes to the instrument once the initial system configuration is completed. The Pro A-RPLC-MS assay was used to demonstrate how a 2D heart-cut approach can be used to transfer an analyte from a matrix that is not MS compatible to a MS-friendly mobile phase so that mass information can also be acquired in a single automated analysis.

References

1. Prentice, K. M.; Wallace, A.; Eakin, C. M. Inline Protein A Mass Spectrometry for Characterization of Monoclonal Antibodies. *Anal. Chem.* 2015, 87, 2023–2028.
 2. Williams, A.; Read, E. K.; Agarabi, C. D.; Lute, S.; Brorson, K. A. Automated 2D-HPLC Method for Characterization of Protein Aggregation with In-Line Fraction Collection Device. *J. Chromatogr. B* 2017, 1046, 122–130.
 3. Sandra, K.; Steenbeke, M.; Vandenheede, I.; Vanhoenacker, G.; Sandra, P. The Versatility of Heart-Cutting and Comprehensive Two- Dimensional Liquid Chromatography in Monoclonal Antibody Clone Selection. *J. Chromatogr. A.* 2017, 1523, 283–292.
-

Featured Products

[ACQUITY UPLC I-Class PLUS System <https://www.waters.com/134613317>](https://www.waters.com/134613317)

[Vion IMS QToF Ion Mobility Quadrupole Time-of-flight Mass Spectrometry <https://www.waters.com/134845751>](https://www.waters.com/134845751)

[UNIFI Scientific Information System <https://www.waters.com/134801359>](https://www.waters.com/134801359)

[ACQUITY UPLC Tunable UV Detector <https://www.waters.com/514228>](https://www.waters.com/514228)

720006691, October 2019

©2019 Waters Corporation. All Rights Reserved.

[Terms of Use](#)

[Privacy](#)

[Trademarks](#)

[Sitemap](#)

[Careers](#)

[Cookies](#)

[Cookie Preferences](#)